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Abstract  
BACKGROUND: Methotrexate (MTX) is the most commonly used disease-modifying drug in the treatment of 
rheumatoid arthritis (RA); however, it causes many side effects, including pulmonary lesions. In this review, we 
characterised the histopathological features of MTX-induced pulmonary lesions in RA patients.  
AIM: We carried out an electronic search of the relevant literature published during the period from 1990 to 2016. 
We included only the cases with definitive histo-pathological findings caused by MTX therapy.  
MATERIAL AND METHODS: The total number of cases is 27. Male: female ratio was 1:3, and ages ranged from 
48 to 87 years old, with a mean (SD) = 65.7 (1.0). The cases were originally from Asia (55%), Europe (41%), and 
America (4%). The major complications of methotrexate therapy were lymphoproliferative disorders (42%) 
followed by interstitial fibrosis (33), and infections (25%). The incidence of these complications significantly 
increases with the duration of MTX treatment (p = 0.044). Among the infections, the most common causative 
organism was pneumocystis jiroveci. The majority of patients who developed infections following methotrexate 
therapy were from Europe whereas the majority of those who developed lymphoproliferative disorders were from 
Asia (p = 0.003).  
CONCLUSION: In conclusion, methotrexate therapy in rheumatoid arthritis patients causes different types 
pulmonary complications. 
 
 
 
 
 
 
Introduction 
 
Rheumatoid arthritis (RA) is a systemic 
inflammatory disorder with articular and extra- 
articular manifestations. The pulmonary complications 
are a well-recognized extra-articular manifestation of 
RA and important cause of morbidity and mortality [1].
 
They include interstitial lung disease, pleural 
thickening, pleural effusions, airways obstruction, 
pulmonary vasculitis and pulmonary hypertension. 
Post-mortem evaluation in RA patients showed a 
possibility of 50% prevalence of pleural involvement 
[2].
  
The lung involvement in these patients is not 
always due to the systemic effects of the disease; the 
therapeutic agents, as well as other causes, are also 
contributing to the pulmonary parenchymal damage 
as adverse side effects. Methotrexate (MTX) is one of 
the widely used drugs in many autoimmune diseases, 
holds a first line drug status in the management of 
rheumatoid arthritis patients, and holds the longest 
duration of a therapeutic segment [3, 4].
 
In many 
clinical trials, methotrexate has been found as an 
effective immunosuppressive agent that efficiently 
slows the progression of the disease; however, it 
causes many side effects such as alopecia, stomatitis, 
gastrointestinal toxicity, liver function abnormalities, 
and pulmonary lesions [4].
  
About 2-7% pulmonary involvement has been 
reported in previous literature, even with a low dose of 
MTX. The reported incidence of pulmonary toxicity 
with methotrexate in RA patients is higher than that of 
liver toxicity. The most prevalent induced MTX 
pulmonary complication is the acute hypersensitivity 
pneumonitis [5].
 
It is estimated that acute pulmonary 
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toxicity develops in about 12.5% of patients on 
methotrexate therapy for all rheumatic conditions, 
including rheumatoid arthritis, but other studies 
suggest an incidence as high as 33% [6, 7].
 
Table 1 
lists the major and the minor criteria for the diagnosis 
of MTX-induced pulmonary complication in 
rheumatoid arthritis patients, and how definite or 
probable cases are diagnosed [8].
 
In correlation with 
clinical features, the histopathological features can be 
valuable in diagnosing drug-induced lung toxicity and 
in guiding treatment interventions. Although the 
surgical lung biopsy is usually large enough to allow 
the pathologist to give a complete description of the 
pulmonary process, a minimally invasive procedure, 
such as bronchoscopic biopsy or Broncho-alveolar 
Lavage (BAL), can provide valuable data [9, 10].
 
The 
histopathological features of MTX-induced pulmonary 
lesions vary from patient to patient, and the present 
evidence provide no definite characteristic for 
pulmonary involvement in these patients [11].
 
In this 
review of case reports, the main objective is to 
characterise the histo-pathological features of MTX-
induced pulmonary lesions in RA patients and to 
investigate the association with the demographic 
features and the duration of treatment. 
Table 1: Diagnostic criteria for the adverse pulmonary events 
associated with methotrexate treatment in rheumatoid arthritis 
patients [8] 
________________________________________________________________________ 
Major 
1. Hypersensitivity pneumonitis by histo-pathologic examination (and without evidence of 
pathogenic organisms) 
2. Radiologic evidences of pulmonary interstitial or alveolar infiltrates  
3. Blood (if febrile) and initial sputum (if produced) cultures negative for pathogenic 
organisms 
Minor 
1. Shortness of breath of <8weeks duration 
2. Non-productive cough 
3. O2 saturation ≤ 90% at the time of initial evaluation on room air 
4. DLCO (Diffusing capacity of carbon monoxide) ≤ 70% of that predicted for age 
5. WBC (White blood cell count) ≤ 15000 per mm
3
 
 Definite cases were defined as the presence of major criteria 1, or major 2 and 3 
and 3 of 5 minor criteria 
 Probable cases: Presence of major criteria 2 and 3 and 2 minor criteria 
________________________________________________________________________ 
 
 
Methodology 
 
An electronic search is carried out for the 
relevant literature published during the period from 
1990 to 2016 in the databases of COCHRANE 
Review, MEDLINE Ovid (from1990 to 2015 November 
25), CINAHL PLUS, Scopus and EMBASE. The 
following search terms “methotrexate” “rheumatoid 
arthritis” “lung lesions” “lung complications” 
“pulmonary lesions” and „pulmonary complications” 
were used along with appropriate Boolean operators 
such as AND or OR. The further search criteria were 
the articles in English language and human adults. 
Also, we used forward as well as backwards chaining 
for the relevant articles cited in retrieved publications 
to get relevant results. We included the case reports 
of adult rheumatoid arthritis patients on methotrexate 
treatment and with findings on histopathology of lung 
lesions. The excluded articles were those reporting 
pulmonary complications due to pulmonary toxic 
agents other than methotrexate. Two authors 
independently searched and retrieved the articles for 
the second stage selection process of reading the title 
and abstract to avoid duplication. During second stage 
evaluation, the same authors analysed for the 
availability of required data in the evidence.
 
 
Inclusion criteria 
1. Case reports on adult rheumatoid arthritis 
patients on methotrexate treatment; 2. Case reports 
with data on histopathology of lung lesions; and 3. 
Articles on both seropositive and negative rheumatoid 
arthritis patients 
 
Exclusion criteria 
1. The use of pulmonary toxic agents other 
than methotrexate and 2. Articles without a description 
of histo-pathological features of lesions. 
 
Figure 1: Flow chart of events in literature search 
 
After removing duplication and reading 
abstracts of retrieved articles, the relevant evidence 
were selected based on the above inclusion and 
exclusion criteria. The data extracted from the 
selected articles were the type of study, year of 
publication, population studied (country), the number 
of patients, age and gender of patients, dose and 
duration of MTX treatment, and pathological 
characters/ features of the lesions. The relevant data 
were analysed using the Statistical Package for the 
Social Sciences (SPSS Inc., Chicago, IL) version 20. 
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Table 2: Descriptions of evidence selected for analysis
 
 
Author /Year/Reference 
 
Country 
 
Gender 
 
Age 
 MTX   
Duration 
 
Type of infection Dose 
Cormelissen, et al., 1991 [12] England Female 71 Low 9 Nocardia Infections 
Hilliquin & Menkes, 1991 [13] France *  Low * E.coli Infections 
Hilliquin & Menkes, 1991 [13] France *  Low * Pneumocystis jiroveci 
Hilliquin & Menkes, 1991 [13] France *  Low * Pneumocystis jiroveci I 
Wollner et al., 1991 [14] England Female 59 Low * Pneumocystis jiroveci 
Okuda et al., 1995 [15] Japan Female 70 Low 2.5 Pneumocystis jiroveci 
Roux et al., 1996 [16] France Female 62 Low 7 Pneumocystis jiroveci 
Roux et al., 1996 [16] France Female 85 Low 8 Pneumocystis jiroveci 
Schnabel et al., 1997 [17] England Female 59 High * Pneumocystis jiroveci 
Schnabel et al., 1997 [17] England Female 66 Low * Interstitial Pneumonitis 
Schnabel et al., 1997 [17] England Female 60 Low * Interstitial Pneumonitis 
Schnabel et al., 1997 [17] England Male 57 Low * Interstitial Pneumonitis 
Eboe et al., 2003 [18] USA Male 54 Low 60  Lymphoproliferative  
Hsu et al., 2003 [19] Taiwan Female 55 Low 54 Interstitial fibrosis 
Shimada et al., 2004 [20] Japan Male 64 Low  Interstitial fibrosis 
Cho et al., 2007 [9] Japan Male 66 Low 5 Interstitial fibrosis 
Kameda et al., 2007 [21] Japan Male 71 Low 24  Lymphoproliferative  
Shimada et al., 2007 [22] Japan Female 54 Low 120  Lymphoproliferative  
Minagawa et al., 2008 [23] Japan Female 62 Low * Interstitial fibrosis 
Inaba et al., 2011 [24] Japan Male 76 Low *  Lymphoproliferative  
Kudoh et al., 2014 [25] Japan Female 75 Low 60  Lymphoproliferative  
Sakai et al., 2014 [26] Japan Female 87 Low 120  Lymphoproliferative  
Tokuyama et al., 2014 [27] Japan Female 68 Low 18  Lymphoproliferative  
Yamakawa et al., 2014 [28] Japan Male 78 Low *  Lymphoproliferative  
Tajima et al., 2015 [29] Japan Female 64 Low 142  Lymphoproliferative  
Akiyama et al., 2015 [30] Japan Female 56 Low 24  Lymphoproliferative  
Koji et al., 2016 [31] Japan Female 48 Low 572  Lymphoproliferative  
* Not Mentioned 
 
 
 
Results 
 
The initial total number of search hits was 
3521 articles. After removing duplications and 
irrelevant results, the number was reduced to 64 
articles. Then after revision of the contents and 
application of the inclusion and exclusion criteria, a 
total of 21 pieces of evidence were selected for 
analysis (Fig 1).  
Twelve pieces of evidence (44%) were 
published during 1990-2000 and 15(56%) evidence 
during  2001-2016. Three pieces of evidence 
presented data of more than one patient, and the total 
number of cases reached 27 (Table 2).  
Male: female ratio was 1:3, ages ranged from 
48 to 87 years old, with a mean (SD) = 65.7 (1.0). 
The cases were originally from Asia (55%), Europe 
(41%), and America (4%) (Fig. 2).  
 
Figure 2: Regional distribution of the case reports 
 
Table 3 shows that the major complications of 
methotrexate therapy were the lymphoproliferative 
disorders (42%) followed by interstitial fibrosis (33), 
and infections (25%), with the insignificant difference 
between the male and female cases (p = 0.191).  
Table 3: Pulmonary Complications of methotrexate therapy 
about gender of the reported cases
 
Complication Male Female Total 
Infections 0 (0%) 6 (25%) 6 (25%) 
Interstitial fibrosis 3 (13%) 5 (21%) 8 (33%) 
Lymphoproliferative disorders 4 (17%) 6 (25%) 10 (42%) 
P = 0.191. 
 
After exclusion of the missing values, the 
duration of treatment had a significant effect on the 
type of pulmonary complications (P = 0.044), Table 4.  
Table 4: Complications of methotrexate therapy in relation to 
duration of treatment 
Complication < 6 month 6 – 18 month > 18 month 
Infections 1 (7%) 3 (21%) 0 (0%) 
Interstitial fibrosis 1 (7%) 0 (0%) 2 (14%) 
Lymphoproliferative disorders 0 (0%) 1 (7%) 6 (43%) 
P= 0.044. 
The majority of patients who developed 
infections following methotrexate therapy were from 
Europe whereas the majority of those who developed 
lymphoproliferative disorders were from Asia (Table 
5). The regional distribution of these lesions was 
statistically significant (P = 0.003). 
Table 5: Regional incidence of MTX induced pulmonary 
complications 
Complication Europe Asia America Total 
Infections 8 (30%) 1 (4%) 0 (0%) 9 (33%) 
Interstitial fibrosis 3 (11%) 5 (18%) 0 (0%) 8 (30%) 
Lymphoproliferative disorders 0 (0%) 9 (33%) 1 (4%) 10 (37%) 
P= 0.003. 
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Discussion 
 
Methotrexate (MTX) is the most common 
disease modifying anti-rheumatoid drug (DMARD) 
used in the treatment of RA patients. It is metabolised 
intracellularly to polyglutamate, which inhibit dihydro 
folate reductase enzyme and other folate-dependent 
enzymes and ultimately causes inhibition of 
chemotaxis and pro-inflammatory cytokine activity 
such as IL-1, IL-2 and IL-6 [32].
 
It exerts both an anti-
inflammatory and immune-modulating effects for the 
management of rheumatoid arthritis [33].
 
The lung 
biopsy performed in patients with MTX pneumonitis 
has demonstrated interstitial inflammation, fibrosis, 
granulomas, giant cells, tissue eosinophils, type II 
pneumocyte hyperplasia and increased intra-alveolar 
macrophages [34].
 
The lung injury induced by 
methotrexate are due to several factors such as 
interference in folate metabolism by methotrexate, 
hypersensitivity reaction to the drug, and impaired 
immunity which predisposes to infection [8, 35]. 
In this review, the authors identified 21 
articles on case reports describing the details of 27 
patients who developed pulmonary lesions while 
receiving methotrexate for the treatment of 
rheumatoid arthritis. The case reports of 12 patients 
were reported during  1990-2000, and the remaining 
cases were reported during the period between 2001 
and 2016. The majority of evidence (55%) are 
published from the Asian continent, followed by 
Europe. Among the nations, the Japanese patients 
are the most dominant. However, this distribution 
does not reflect the geographical prevalence of RA. 
With the exclusion of 3 unmentioned data about the 
gender of some patients, a higher rate of pulmonary 
complications are reported among the females 
compared to the males. This gender variation in MTX-
induced pulmonary lesions is most probably due to 
the higher prevalence of RA among the females 
compared to the males [36]. 
We found an insignificant age-related 
difference in the development of pulmonary 
complications due to MTX therapy. The histo-
pathological examinations of lung biopsy samples in 
this review revealed three major categories of 
pulmonary lesions: infections (25%), interstitial fibrosis 
(33%) and lymphoproliferative disorders (42%). The 
high incidence of lymphoproliferative disorders may 
be due to the propensity of RA Patients to develop 
Ebstein Barr viral infection, secondary to methotrexate 
induced iatrogenic immunodeficiency [35].
 
The 
incidence of these disorders significantly increases 
with the duration of MTX treatment. However, there is 
no significant gender-related difference for these 
lesions. Among the infections, the most common 
causative organism was pneumocystis jiroveci, which 
affected seven patients of the infection group. The 
superimposed pulmonary infection attributed to the 
immunosuppressive status with opportunistic 
infectious agents, notably pneumocystis and nocardia, 
is one of the prime notified complication associated 
with MTX therapy [34].
 
The incidence of infection is 
higher in European region when compared to other 
regions whereas the incidence of lymphoproliferative 
disorders is higher among the Asian patients. 
In this study, we could not exclude the 
pulmonary effects of the other medications that were 
used in combination with the MTX, and not excluded 
because they are not known to be pulmono- toxic. On 
the other hand, the exclusion of the patients who 
received known pulmono-toxic agents in addition to 
methotrexate caused a large reduction in the number 
of our cases. Another limitation of this study are the 
direct effects of rheumatoid arthritis on the pleura and 
lung parenchyma. Also, the impure preparation of 
methotrexate in some laboratories is a recognised 
cause of toxicity [33]. 
In conclusion, methotrexate therapy in 
rheumatoid arthritis patients causes three categories 
of pulmonary lesions: lymphoproliferative disorders 
(42%), interstitial fibrosis (33), and infections (25%). 
The incidence of these complications significantly 
increases with the duration of MTX treatment. Among 
the infections, the most common causative organism 
was pneumocystis jiroveci. Further reviews are 
recommended to evaluate its side effects in 
comparison with the side effects of the other immuno-
suppressive agents. 
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